352 related articles for article (PubMed ID: 29663363)
1. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
[TBL] [Abstract][Full Text] [Related]
2. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort.
Vink FJ; Lissenberg-Witte BI; Meijer CJLM; Berkhof J; van Kemenade FJ; Siebers AG; Steenbergen RDM; Bleeker MCG; Heideman DAM
Clin Microbiol Infect; 2021 Jan; 27(1):125.e1-125.e6. PubMed ID: 32222459
[TBL] [Abstract][Full Text] [Related]
3. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
Dick S; Kremer WW; De Strooper LMA; Lissenberg-Witte BI; Steenbergen RDM; Meijer CJLM; Berkhof J; Heideman DAM
Gynecol Oncol; 2019 Aug; 154(2):368-373. PubMed ID: 31182225
[TBL] [Abstract][Full Text] [Related]
4. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
Bonde J; Floore A; Ejegod D; Vink FJ; Hesselink A; van de Ven PM; Valenčak AO; Pedersen H; Doorn S; Quint WG; Petry KU; Poljak M; Stanczuk G; Cuschieri K; de Sanjosé S; Bleeker M; Berkhof J; Meijer CJLM; Heideman DAM
Int J Cancer; 2021 Jan; 148(2):396-405. PubMed ID: 32997803
[TBL] [Abstract][Full Text] [Related]
5. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
Vink FJ; Meijer CJLM; Clifford GM; Poljak M; Oštrbenk A; Petry KU; Rothe B; Bonde J; Pedersen H; de Sanjosé S; Torres M; Del Pino M; Quint WGV; Cuschieri K; Boada EA; van Trommel NE; Lissenberg-Witte BI; Floore AN; Hesselink AT; Steenbergen RDM; Bleeker MCG; Heideman DAM
Int J Cancer; 2020 Aug; 147(4):1215-1221. PubMed ID: 31390052
[TBL] [Abstract][Full Text] [Related]
6. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.
De Strooper LMA; Verhoef VMJ; Berkhof J; Hesselink AT; de Bruin HME; van Kemenade FJ; Bosgraaf RP; Bekkers RLM; Massuger LFAG; Melchers WJG; Steenbergen RDM; Snijders PJF; Meijer CJLM; Heideman DAM
Gynecol Oncol; 2016 May; 141(2):341-347. PubMed ID: 26921784
[TBL] [Abstract][Full Text] [Related]
7. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ
Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579
[TBL] [Abstract][Full Text] [Related]
8. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.
Vink FJ; Meijer CJLM; Hesselink AT; Floore AN; Lissenberg-Witte BI; Bonde JH; Pedersen H; Cuschieri K; Bhatia R; Poljak M; Oštrbenk Valenčak A; Hillemanns P; Quint WGV; Del Pino M; Kenter GG; Steenbergen RDM; Heideman DAM; Bleeker MCG
Clin Infect Dis; 2023 Feb; 76(3):e827-e834. PubMed ID: 35686306
[TBL] [Abstract][Full Text] [Related]
9. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of
Kremer WW; Dick S; Heideman DAM; Steenbergen RDM; Bleeker MCG; Verhoeve HR; van Baal WM; van Trommel N; Kenter GG; Meijer CJLM; Berkhof J
J Clin Oncol; 2022 Sep; 40(26):3037-3046. PubMed ID: 35512257
[TBL] [Abstract][Full Text] [Related]
10. Cervix cytology samples revealed increased methylation of the human markers FAM19A4/miR124-2 up to 8 years before adenocarcinoma.
Lindroth Y; Pedersen L; Alssamaray J; Berglund T; Sundqvist A; Borgfeldt C; Forslund O
Acta Obstet Gynecol Scand; 2024 Feb; 103(2):378-386. PubMed ID: 37964497
[TBL] [Abstract][Full Text] [Related]
11. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
12. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG
Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239
[TBL] [Abstract][Full Text] [Related]
13. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions.
De Strooper LM; Meijer CJ; Berkhof J; Hesselink AT; Snijders PJ; Steenbergen RD; Heideman DA
Cancer Prev Res (Phila); 2014 Dec; 7(12):1251-7. PubMed ID: 25281488
[TBL] [Abstract][Full Text] [Related]
14. The use of molecular markers for cervical screening of women living with HIV in South Africa.
Kremer WW; van Zummeren M; Breytenbach E; Richter KL; Steenbergen RDM; Meijer CJLM; Dreyer G
AIDS; 2019 Nov; 33(13):2035-2042. PubMed ID: 31385866
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
Dick S; Vink FJ; Heideman DAM; Lissenberg-Witte BI; Meijer CJLM; Berkhof J
Br J Cancer; 2022 Feb; 126(2):259-264. PubMed ID: 34743198
[TBL] [Abstract][Full Text] [Related]
16. Complementarity between miRNA expression analysis and DNA methylation analysis in hrHPV-positive cervical scrapes for the detection of cervical disease.
Babion I; De Strooper LMA; Luttmer R; Bleeker MCG; Meijer CJLM; Heideman DAM; Wilting SM; Steenbergen RDM
Epigenetics; 2019 Jun; 14(6):558-567. PubMed ID: 30955437
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
[TBL] [Abstract][Full Text] [Related]
18. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women.
Hampl M; Hesselink AT; Meijer CJLM; Denecke A; Einhorn I; Reinecke-Luethge A; Geppert CI; Jentschke M; ; Petry KU; Hillemanns P
Int J Cancer; 2022 Nov; 151(9):1578-1585. PubMed ID: 35666529
[TBL] [Abstract][Full Text] [Related]
20. Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions.
Leeman A; Jenkins D; Del Pino M; Ordi J; Torné A; Doorbar J; Meijer CJLM; van Kemenade FJ; Quint WGV
Cancer Med; 2020 Apr; 9(7):2454-2461. PubMed ID: 32022461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
